Key Highlights

  • 0.95 is the loss per share in USD implied by the consensus EPS estimate of -0.95 for Immunic, Inc. (NASDAQ:IMUX), which reports third quarter 2026 results before the market opens on November 13, 2026.
  • 0.80 USD was the second quarter 2026 loss per share on a net loss of about USD 34.1 million, versus a loss of USD 2.03 per share and USD 26.8 million in the second quarter of 2025.
  • 155.1 million USD was the cash balance at June 30, 2026, and management expects it to fund operations into late 2027, following a February 2026 private Placement that lifted interest income to USD 1.3 million.
  • 110.79 million USD is the market Capitalization per the screener snapshot, while top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials in relapsing multiple sclerosis are expected by the end of 2026.

What Investors Expect From Immunic, Inc. (NASDAQ:IMUX) on November 13, 2026

Per the screener snapshot, Immunic, Inc. reports third quarter 2026 results on November 13, 2026, before the market opens, with a consensus EPS estimate of -0.95 and a market capitalization of USD 110.79 million. The estimate compares with a second quarter loss of USD 0.80 per share, and a larger gap would reflect a different weighted share count. For the third quarter of 2025, published coverage cited a net loss of USD 25.6 million. The call time was not detailed in the snapshot.

The Rationale: Last Reported Quarter and Management Outlook for Immunic, Inc. (NASDAQ:IMUX)

In the second quarter of 2026, Research and Development expense was USD 25.9 million, up from USD 21.3 million, and general and administrative expense rose to USD 9.4 million from USD 5.7 million, for total operating expenses of USD 35.3 million. Non-cash charges, mainly stock compensation, were USD 7.2 million. The six-month net loss was about USD 66.7 million, or USD 1.83 per share. Management said the ENSURE data are due by the end of 2026, with a US NDA planned for mid-2027 and a targeted approval in 2028. A Phase 3 trial in progressive multiple sclerosis is planned to start later in 2026. Chief Executive Officer Erik Lundgren said the company is well capitalized to execute on its priorities.

Valuation, Liquidity and Risks for Immunic, Inc. (NASDAQ:IMUX)

Cash of USD 155.1 million at June 30, 2026 compares with second quarter operating expenses of USD 35.3 million, so quarterly spending equals about 23% of the cash balance (calculated). Weighted-average shares were 42,513,839 in the second quarter, versus 13,217,520 a year earlier. The company has no product Revenue and gave no revenue or expense guidance. Risks include binary trial outcomes, regulatory timing, dilution and further financing needs beyond late 2027. A year-over-year increase of about 27% in the second quarter net loss (calculated) shows rising spending.

Where Things Stand

Where things stand: Immunic, Inc. (NASDAQ:IMUX) reports with a consensus EPS estimate of -0.95, a snapshot market capitalization of USD 110.79 million and USD 155.1 million of cash at June 30, 2026. Spending reached USD 35.3 million in the second quarter as late-stage multiple sclerosis work and drug-interaction studies for a potential NDA continued. Management expects funding into late 2027 and top-line ENSURE results by the end of 2026, which makes the call commentary on timing central. The company has no revenue, so results turn on expenses, interest income and share count. This is information only and not Investment advice.